相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Amy D. Guertin et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
Aki Iwai et al.
CELL CYCLE (2012)
WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis
Sireesha V. Garimella et al.
MOLECULAR CANCER RESEARCH (2012)
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Jenny M. Kreahling et al.
MOLECULAR CANCER THERAPEUTICS (2012)
High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
Gry Irene Magnussen et al.
PLOS ONE (2012)
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
Jantine PosthumaDeBoer et al.
BMC CANCER (2011)
Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Kurtis D. Davies et al.
CANCER BIOLOGY & THERAPY (2011)
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2011)
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Kathleen A. Bridges et al.
CLINICAL CANCER RESEARCH (2011)
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Raquel Dominguez-Kelly et al.
JOURNAL OF CELL BIOLOGY (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson et al.
NATURE MEDICINE (2011)
Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1
Yuse Martin et al.
CELL DIVISION (2011)
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome
Lyndsay M. Murrow et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil
Hiroshi Hirai et al.
CANCER BIOLOGY & THERAPY (2010)
In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
Shahryar E. Mir et al.
CANCER CELL (2010)
Hsp90 phosphorylation, Wee1, and the cell cycle
Mehdi Mollapour et al.
CELL CYCLE (2010)
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
Halfdan Beck et al.
JOURNAL OF CELL BIOLOGY (2010)
Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function
Mehdi Mollapour et al.
MOLECULAR CELL (2010)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Neil Johnson et al.
MOLECULAR CELL (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns et al.
PLOS ONE (2009)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
A concise review of DNA damage checkpoints and repair in mammalian cells
Jaco H. Houtgraaf et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2006)
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
A Jazayeri et al.
NATURE CELL BIOLOGY (2006)
CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair
F Esashi et al.
NATURE (2005)
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
CS Sorensen et al.
NATURE CELL BIOLOGY (2005)
Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis
YL Wang et al.
CANCER BIOLOGY & THERAPY (2004)
DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1
G Ira et al.
NATURE (2004)
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
SF El-Khamisy et al.
NUCLEIC ACIDS RESEARCH (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis
T Masaki et al.
HEPATOLOGY (2003)
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
S Matsuoka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
